HCPCS Code Q5110: Filgrastim-aafi Injection, Biosimilar

Learn about HCPCS Code Q5110 for accurate billing and coding.

Filgrastim-aafi is the proper name for the biosimilar marketed as Nivestym. It is a granulocyte colony-stimulating factor within the class of colony-stimulating factors. The generic base name filgrastim refers to the active substance. Clinicians use Filgrastim-aafi to reduce the risk of infection and severe neutropenia in nonmyeloid malignancies receiving myelosuppressive chemotherapy or myelosuppressive anti-cancer drugs. It also supports mobilization of peripheral blood stem cells for collection, care after bone marrow transplant, and chronic neutropenia states that include congenital neutropenia, idiopathic neutropenia, and cyclic neutropenia. Administration of filgrastim is by subcutaneous injection, intravenous infusion, or short intravenous infusion. Dosing is weight-based and follows a recommended dose that targets timely neutrophil recovery. Trials without prophylaxis show a significant incidence of febrile neutropenia. Q5110 is not a diagnostic injection. There is investigational and off-label interest in colony-stimulating factors, including filgrastim, for Crohn's disease. Filgrastim-aafi is not an FDA-approved or routine therapy for Crohn’s disease, and its primary indications remain neutropenia management and stem cell mobilization in cancer and related conditions.

## **Q5110 documentation requirements** Accurate records are essential to support medical necessity and clean claim processing. ### **Patient and provider identifiers** Include patient identification details, payer information, the rendering clinician’s name, National Provider Identifier, and any payer-specific provider ID. Capture the place of service with the correct code. ### **Medical necessity and diagnosis codes** Link the service to clear diagnosis codes that justify use, such as chemotherapy-induced neutropenia in nonmyeloid malignancies, care after myeloablative chemotherapy, mobilization of peripheral blood stem cells, or chronic neutropenia conditions. Note whether the clinical situation involves symptomatic patients. ### **Drug and unit details** Record the drug name Filgrastim-aafi Nivestym, the HCPCS code Q5110, the National Drug Code, strength and vial size, the exact number of units administered, where 1 unit equals 1 microgram, the route as subcutaneous injection or intravenous infusion, and the frequency. ### **Administration and wastage** Document the administration procedure and the corresponding modifiers for the administration route. State whether any amount was discarded and quantify the waste if applicable. Do not bill a separate CPT code. ### **Clinical course and plan** Summarize the indication and the planned course, such as post-induction or consolidation chemotherapy treatment for acute myeloid leukemia, post-transplant support after bone marrow transplant, or mobilization before collection of autologous hematopoietic progenitor cells. Include goals for neutrophil recovery and the monitoring plan.

## **Q5110 billing requirements** Submit claims that mirror the medical record and follow payer guidance. ### **Units and conversions** Bill Q5110 in micrograms. One billing unit equals 1 microgram of Filgrastim-aafi. A 300 microgram dose requires 300 units. A 480 microgram dose requires 480 units. ### **Modifiers for route and wastage** Append JA for intravenous infusion and JB for subcutaneous injection to indicate the route. Use JW for discarded drug amounts when waste is documented. Use JZ to attest zero waste when the entire single-dose vial was used without discard. ### **Claim form essentials** On CMS-1500, enter Q5110 and the administration CPT code in the procedures field, link the diagnosis codes, and report the total units administered. On UB-04, report the HCPCS, modifiers, revenue codes, and unit count that matches the administered micrograms. Include the National Drug Code when the payer requires it. ### **Medical policy checks** Verify prior authorization when required. Follow payer limits for quantities and frequency. Use the recommended dose per labeled or policy-accepted regimens for myelosuppressive chemotherapy, myeloablative chemotherapy, or mobilization of autologous hematopoietic progenitor cells. ### **Compliance reminders** Do not overbill units. Do not add waste beyond what is supported by documentation. Ensure administration codes and modifiers match the recorded route and timing.

## **Q5110 applicable modifiers** Use these route and wastage modifiers to keep claims compliant: - JA: Intravenous administration for intravenous infusion or short intravenous infusion. - JB: Subcutaneous route for subcutaneous injection. - JW: Drug amount discarded when part of a single-dose vial is not administered. - JZ: Zero drug wasted when the entire single-dose vial is used. Always confirm payer-specific instructions before submitting the claim.

## **Other relevant codes** Use related codes when they better describe the product or when you need an administration code: - J1442: Injection, filgrastim, excludes biosimilars, 1 microgram. - Q5101: Injection, filgrastim-sndz, biosimilar, Zarxio, 1 microgram. - J1447: Injection, tbo-filgrastim, 1 microgram. - Q5111: Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 micrograms. - 96372: Therapeutic injection administration for subcutaneous injection. - 96365: Initial intravenous infusion up to one hour when payer policy supports IV infusion billing for this service.

Frequently asked questions

HCPCS Q5110 should be billed with the JA modifier for IV administration or the JB modifier for subcutaneous administration. The drug administration is included in the Q5110 billing with the proper modifier, so separate billing of an infusion CPT code like 96365 is not typically required or appropriate.

Bill one unit per microgram administered. Convert the dose to micrograms and enter that number as the units. Ensure the units on the claim match the documented dose and any waste is reflected with JW or JZ as required.

Filgrastim-aafi is not an FDA-approved or routine therapy for Crohn's disease. Research has explored colony-stimulating factors as investigational or off-label approaches in moderate to severe active Crohn’s disease, but Q5110 billing is focused on approved uses in neutropenia management and stem cell mobilization.